Alternate prime/boost vaccination regimens employing recombinant replication-deficient adenovirus or MVA, expressing Influenza A virus nucleoprotein and matrix protein 1, induced antigen-specific T cell responses in intradermally (ID) vaccinated mice; with the strongest responses resulting from Ad/MVA immunization. In BALB/C mice the immunodominant response was shifted from the previously identified immunodominant epitope to a novel epitope when the antigen was derived from A/Panama/2007/1999 rather than A/PR/8. Alternate immunization routes did not affect the magnitude of antigen-specific systemic IFN-c response, but higher CD8 1 T-cell IFN-c immune responses were seen in the bronchoalveolar lavage following intransal (IN) boosting after intramuscular (IM) priming, whilst higher splenic antigen-specific CD8 1 T cell IFN-c was seen following IM boosting. Partial protection against heterologous influenza virus challenge was achieved following either IM/IM or IM/IN but not ID/ID immunization. These data may be of relevance for the design of optimal immunization regimens for human influenza vaccines, especially for influenza-naïve infants.
I nfluenza vaccines in current use induce protective antibodies against the highly polymorphic external viral glycoprotein haemagglutinin (HA). However frequent changes in composition and annual revaccination are required to maintain effective immunity because of the constant genetic drift in HA sequences of seasonal influenza viruses. In addition, seasonal influenza vaccinations are not effective against pandemic influenza, and there is now some evidence that recent seasonal influenza infection, rather than vaccination, may result in some protection against pandemic influenza 1, 2 . A vaccine that could protect against all subtypes of influenza A virus, with the same or greater efficacy against seasonal influenza as currently licensed vaccines has been the focus of much research effort 3, 4 . The availability of such vaccines could bring about a major improvement in protection of the population from both seasonal and pandemic influenza 5 with considerable economic benefits. To achieve this will require a fundamental change in the composition and mode of action of influenza vaccines. Much pre-clinical research has focussed on protective T cell responses to internal influenza antigens such as nucleoprotein (NP) and matrix protein 1 (M1). Compared to the external viral glycoproteins, the conservation between these antigens derived from influenza A viruses of different subtypes is generally high; typically over 90% identical at the amino acid level. Human T cells specific for these antigens, and others, acquired following natural exposure to seasonal influenza have been shown to crossreact with H5N1 antigens 6 . In pre-clinical studies, vaccination with DNA or adenovirus vectors expressing influenza NP induced NP-specific T cell responses, and a high level of protection was seen after challenge with a heterosubtypic virus, although the immunodominant epitope (NP [147] [148] [149] [150] [151] [152] [153] [154] [155] ) in the BALB/c mouse strain that was studied is completely conserved between the vaccine and challenge virus 7 . In a further study, heterosubtypic protection was demonstrated in C57BL/6 mice despite 2 amino acid differences in the immunodominant NP 366-374 between the adenovirus-vectored vaccine and challenge virus antigen ( Table 1 ) thereby suggesting that heterosubtypic protection is achievable in this model.
Recombinant replication-deficient viral vectors are potent immunogens capable of both priming and boosting T cell responses against the recombinant antigens they encode. They are highly immunogenic in humans, and this, combined with their excellent safety profile, makes them ideal vectors for inducing protective T cell responses to influenza antigens. In clinical studies they have been administered by intradermal or intramuscular administration 8 , but pre-clinical studies have assessed mucosal immunization, including via intranasal administration, and demonstrated higher immune responses in the respiratory tract and greater protection against virus challenge following intranasal delivery 9 . Intranasal immunization is used for licensed live attenuated influenza vaccines (LAIV), and could potentially be used for recombinant viral vectors. However, the delivery devices required for intranasal or aerosolised immunization are more expensive to produce than needles and syringes used for intramuscular or intradermal vaccination. Despite being less invasive to use, the device used for LAIV administration generates large particle sizes that are less effective in vaccine delivery and can cause vaccine to drip out of the nose or roll back into the pharynx, reducing vaccine acceptability and efficacy 10 . LAIV is licensed for use in children over the age of two years, but in infants aged between 6 months and two years use of intranasal LAIV resulted in a greater number of hospitalizations due to wheezing 11 . However, pre-clinical studies have indicated that intramuscular vaccination can prime strong mucosal responses 12, 13 , and this route of vaccination may therefore allow safe priming of mucosal responses in infants without the need for delivery of vaccine directly to the respiratory tract. As infants are among the most susceptible members of the population to influenza virus infection, we wished to test a vaccination regimen that could be safely and effectively used in infants, whilst still inducing protective immune responses. We therefore employed alternate vaccination regimens, including intradermal prime-boost or intramuscular priming followed by either intranasal or intramuscular boosting. Intradermal administration of seasonal influenza subunit vaccine has been shown to result in significantly higher immune responses (HI titres) than intramuscular administration in elderly adults 14 and may also be an appropriate immunization route for infants.
In this pre-clinical study we have tested the use of recombinant replication-deficient viral-vectored vaccines that are suitable for use in humans to induce protective T cell responses against influenza NP and M1. We found a high level of protection against influenza virus challenge despite differences in the immunodominant epitope. Systemic influenza-directed T cell responses were similar in the intramuscular and intradermal vaccination regimens but improved survival following heterologous influenza challenge was seen following intramuscular but not intradermal vaccination. There were differences in CD8
1 T cell responses in the systemic (spleen) and local (lungs and bronchoalveolar lavage (BAL)) immune responses within days following intranasal vaccination when compared to intramuscular or intradermal administration. However, similar levels of protection following influenza virus challenge were achieved following intranasal or intramuscular boosting, despite the increased influenza-directed T cell response in the BAL following intranasal boosting and lower splenic T cell responses.
Results
The vaccine regimen employing recombinant replication-deficient adenovirus (Ad) priming followed by recombinant Modified Vaccinia Ankara (MVA) boosting has been demonstrated to be highly immunogenic for the induction of both antigen-specific CD4 1 and CD8
1 T cells 15, 16 . We tested four alternative prime-boost regimens employing these viral vectors expressing NP and M1 from A/ Panama/2007/1999, administered intradermally (ID). In both the spleen and lymph nodes the Ad prime/MVA boost regimen was most immunogenic, inducing T cell responses more than three-fold higher than co-administration of the vaccines or homologous prime/boost with either vaccine when assayed by interferon-c ELISpot ( Figure 1 ). The Ad prime/MVA boost regimen with an eight week interval between prime and boost was then adopted for all further experiments.
We then determined the response to individual 18-20 mers spanning the NP1M1 antigen, 3 weeks following a single ID immunization with Ad-NP1M1. However, with respect to CD8
1 T cell responses, from the initial peptide matrix study, we identified three peptides that induced IFN-c 1 responses from immunized mice ( Figure 2 We also analysed the quality of the CD8 1 T cells induced by these different regimens before boosting and at short intervals after boosting mice by the IM or IN route with MVA-NP1M1 ( Figure 5 ). In the lung, polyfunctional CD8
1 T cells trended toward higher frequencies (Figure 4) , we then conducted influenza virus challenge experiments to determine the relative protective efficacy of alternate immunization regimens. C57BL/6 mice were immunised as before, and subsequently challenged by intranasal administration of A/PR8 virus six week after MVA boosting (Figure 6a ). Samples were taken from four of the animals in each group prior to challenge to assay peripheral blood mononuclear cells (PBMC) responses to NP and M1 by IFN c 
Discussion
There are numerous studies, supporting the role for both CD8 1 and CD4 1 T cells in combating influenza infection and subsequent illness (reviewed by Ref. [18] [19] [20] [21] , as such, there is a concerted drive to develop vaccines that can efficaciously induce influenza-directed T cell immunity. T cell responses specific for the relatively well conserved internal influenza antigens are an important component of naturally acquired immunity to influenza, especially against heterosubtypic viruses. Inactivated influenza vaccines have a minimal effect on boosting these responses 22 , and there is an increasing body of evidence that recent vaccination with TIV (Trivalent Influenza Vaccine) could increase susceptibility to infection with a virus not included in the vaccine, by preventing infection with the viruses matched to the vaccine and thereby preventing the acquisition of cellular immune responses to conserved antigens 1, [23] [24] [25] [26] . This heterosubtypic protection is not expected to completely prevent infection with influenza virus, but to result in a mild, possibly sub-clinical infection, reduction in virus shedding and rapid recovery rather than a severe illness or death. Combined with a humoral response, the breadth of which may be increased at least within subtype to allow recognition of drifted variants, this could result in complete protection against influenza subtypes included within the vaccine and additionally and importantly, partial protection against all other subtypes which might circulate in the event of a new pandemic.
The novel influenza vaccine MVA-NP1M1 has been tested for safety, immunogenicity and efficacy in clinical trials. Safety is as expected for MVA-vectored vaccines, which generally cause some mild or moderate adverse events within the first two days after vaccination, but these resolve quickly, and the complete inability of MVA to replicate after immunization makes the vaccines safe to use in all sections of the population. A single dose of MVA-NP1M1 resulted in a large expansion of NP and M1-specific T cells in volunteers, with responses still above pre-vaccination levels a year after vaccination 27 . In an influenza challenge trial, there was a significant reduction in the duration of virus shedding in vaccinated compared to unvaccinated volunteers, as well as a reduction of symptoms in the vaccinated group 28 . However the vaccine has only been tested in volunteers over the age of 18 years, who all had pre-existing CD4 1 and CD8 1 responses to the vaccine antigens as a result of prior exposure to influenza virus. For infants and young children, a priming immunization will be required. The simian adenovirus vaccine vector ChAdOx1 29 is now being tested in a Phase I clinical trial, and this will be followed by ChAdOx1 and MVA prime boost clinical studies. However it is important to determine the best route for immunization to achieve the maximum level of protection with these viral vectored vaccines, and to consider whether, despite the high level of conservation of NP and M1, a small number of amino acid changes in key epitopes could result in diminished immunogenicity and protection.
In this pre-clinical study we have examined the effect of priming and boosting T cell responses to one naturally occurring NP sequence and challenging with a virus expressing a different one. We found that in C57BL/6 mice the immunodominant epitope within NP varied depending on the sequence that was used to immunise. By examining the response to peptides spanning the entire antigen rather than only the known immunodominant epitope we were able to identify a novel immunodominant epitope present in some NP sequences. The pattern of NP 366-74 dominating after immunization with PR8 NP, but NP 335-352 dominating after immunization with Panama NP was found in mice immunised with replication deficient adenovirus, or DNA vaccine (data not shown) priming, then MVA boosting, reinforcing the idea that this shift in immunodominance is a feature of the NP sequences themselves rather than the vectors used to deliver them.
We also examined the effect of immunization route on immunogenicity and protection. Following the discovery that ID administration of MVA was more protective in a mouse malaria challenge model than IM 30 , early clinical trials of MVA-vectored malaria vaccines 31 and TB vaccines 32 employed ID immunization. However this presents some practical difficulties; the volume that can be delivered by this route is only about 10% of that which can be delivered by IM immunization, and ID immunizations are considerably more technically demanding to perform. This led to a switch to IM immunizations for malaria vaccines 16 , and a comparison of the same dose of MVA-NP1M1 delivered by either route in a clinical trial concluded that there was no significant difference in immunogenicity as measured by the IFN-c ELISpot assay in peripheral blood 27 . Some pre-clinical studies have demonstrated that mucosal vaccination leads to higher mucosal immune responses 33 , and this is important for a respiratory tract pathogen such as influenza virus. However, despite the use of an intranasal spray to deliver LAIV vaccine, there are some disadvantages to this mode of administration in infants. We therefore wished to examine IM priming followed by IN boosting, as this has been used effectively in pre-clinical studies to induce high level mucosal responses 12, 13 . This would allow infants to be vaccinated IM, which is easier to employ in that age group, followed by a subsequent IN boost in childhood, to enhance mucosal immunity further. We found that while responses in the spleen following IM/IN immunization were slightly lower than either ID/ID or IM/IM, responses in the lung and BAL were higher, confirming that it is sufficient for the boost to be given IN to achieve strong mucosal responses. In influenza virus challenge experiments, IM/IM was more protective than ID/ID, which was surprising given the similar level of systemic CD8 1 T cell immunogenicity following both vaccination regimens. However, it has been demonstrated that environmental factors (antigen presenting cell, cytokines, chemokines and mode of antigen presentation) at the site of antigen exposure can induce differential expression of tissue-selective homing lymphocytes receptors 34 and may therefore impact on sequential responses following repeat exposure to antigen. Indeed, direct antigen presentation appears to be more important for intramuscular, compared to the intradermal, induction of cytotoxic CD8
1 T cells to Vaccina virus 35 , and different tissue-specific dendritic cells have also been found to lead to different outcomes in the induction of regulatory T cells 36 which may in turn affect antigen-specific responses. There was no significant difference in protection against influenza virus challenge six weeks after either intranasal or intramuscular boosting following intramuscular priming despite the observed differences in mucosal immunity two weeks after boosting. This was also observed in a second mouse strain challenged with two different influenza viruses.
As has been seen in other studies of heterosubtypic rather than homosubtypic influenza virus challenge 7, 23 , protection is not always complete, but is achieved despite sequence changes in the challenge virus in both the previously known immunodominant epitope in NP PR8 and the newly identified immunodominant epitope in NP Panama. Thus the level of polymorphism that is found in internal antigens of influenza A viruses capable of infecting humans should not present a barrier to achieving useful protection through T cell responses to these antigens.
The route of immunization is important for protection, with both IM/IN and IM/IM regimens providing a higher degree of protection than ID/ID. However, stronger immune responses in the BAL following IN rather than IM boosting with MVA perhaps surprisingly did not result in improved protection against IN virus challenge. This www.nature.com/scientificreports is an important finding, indicating that in clinical trials it will not be sufficient to assess mucosal immunity to predict vaccine efficacy. Further vaccine development (efficacy as well as immunogenicity) in relevant animal models (e.g. the pig) could provide a useful way of developing the most protective immunization regimens for use in infants, in which the aim will be to prime an immune response that forms the basis of lifelong broad immunity to influenza rather than providing short term protection against specific HA sequences.
Methods
Ethics statement. All mouse procedures were performed in strict accordance with the terms of licences from the UK Home Office, under the terms of the Animals (Scientific Procedures) Act 1986 (licence numbers 30/2889 and 30/241 and the Irish Department of Health and Children, under the Cruelty to Animals Act (licence numbers B100/4034 and B100/3157) and 4) and according to the approval of the UCC AECC and University of Oxford Animal Ethics Committees.
Vaccines. MVA-NP1M1 expresses NP and M1 from A/Panama/2007/1999 as a single fusion antigen and is described in 27 . A replication-deficient E1E3 deleted adenovirus Hu5 expressing the same antigen under the control of a CMV promoter was also used.
Animals and immunizations. Female Balb/c or C57BL/6 mice of 6 weeks of age or older (Harlan, UK) were immunized intramuscularly (IM) in the musculus tibialis, intradermally (ID) in the ear, or intranasally (IN) with a total volume of 50 ml of vaccine diluted in PBS. For all murine immunizations AdHu5 was administered at 5 3 10 9 vp and MVA was administered at 10 6 pfu unless otherwise indicated.
ELISpots. Murine spleens or peripheral blood samples were treated with ACK lysis buffer to remove RBCs prior to stimulation with the relevant peptides (final concentration of 5 mg/ml) on IPVH-membrane plates (Millipore) coated with 5 mg/ml anti-mouse IFN-c (AN18). After 18-20 hours of stimulation, IFN-c spot forming cells (SFC) were detected by staining membranes with either anti-mouse IFN-c biotin (1 mg/ml) (R46A2) followed by streptavidin-Alkaline Phosphatase (1 mg/ml) and development with AP conjugate substrate kit (BioRad, UK).
Intracellular cytokine staining. Murine splenocytes were stimulated for a total of 2 hours with a single pool containing whole NP1M1 peptides (10 mg/ml final concentration) or media only (unstimulated control), with the addition of Golgi-Plug and Golgi-Stop (BD) (0.2 uL Golgi-Plus and 0.2 uL Golgi-stop per 1 3 10 6 splenocytes) for the final 4 hours. Following surface staining with CD4-efluor 650, CD8 PerCPCy5.5, CD62L-APC-ef 780 and CD127-PE-CY7, cells were fixed with 4% paraformaldehyde and stained intracellularly with TNF-á FITC, IL-2 PE and IFN-ã APC (or in some instance, IFN-ã eflour 450) and diluted in Perm-Wash buffer (BD). Sample acquisition was performed on a LSR II and data analyzed in FlowJo (TreeStar).
Influenza virus challenge. Six weeks following the last immunization mice were challenged with A/PR/8/34, (PR8), A/X-31(H3N2) (X31) or E61-13-H17 (H17) influenza virus. Mice were anesthetized with 100 mL of ketamine/dormitor administered via intraperitoneal injection (i.p.). Virus was inoculated intranasally in a volume of 50 mL. PR8 was administered at 20-25 PFU, X31 at 10 6.5 TCID50/ml, an and H17 at 10 4.5 TCID50/ml. Mice were monitored daily for 10 days or more for clinical disease, symptoms including weight loss, piloerection, and reduced motility. A 20% reduction in bodyweight was defined as a humane endpoint and animals meeting this criterion were euthanized.
